Champions Oncology Q4 revenue rises; margin improves driven by cost discipline
Champions Oncology Q4 revenue rises; margin improves driven by cost discipline
Overview
US oncology research provider's fiscal Q4 revenue rose 12% yr/yr to $13.8 mln
Company posted positive adjusted EBITDA and adjusted EPS of $0.01 for the quarter
Improved margins driven by cost discipline and in-house radiopharmaceutical transition
Outlook
Company did not provide specific guidance for future quarters or fiscal year
Result Drivers
COST DISCIPLINE - Co said lower outsourced research services expenses and compensation reduced cost of revenue, supporting higher margins
IN-HOUSE TRANSITION - Co said moving certain radiopharmaceutical activities in-house lowered costs and improved margins
STRATEGIC INVESTMENTS - Co continued to invest in commercial organization and data platform, increasing operating expenses
Company press release: ID:nACSVT9lsa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue |
| $13.80 mln |
|
Q4 Adjusted EPS |
| $0.01 |
|
Q4 Loss Per Share |
| $0.05 |
|
Analyst Coverage
The stock recently traded at 59 times the next 12-month earnings vs. a P/E of 56 three months ago
Reuters Recommended Reads
July 27 - AstraZeneca drug prices evolving in response to Trump policy, executive says
July 27 - Sarepta names former Abbvie president as CEO as Ingram retires
July 24 - FDA advisers recommend relaxing US rules on compounding peptides
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)